{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:52:37Z","timestamp":1787755957179,"version":"build-2784847793"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the first-line treatment patterns and prognostic factors associated with survival in patients with driver gene-negative non-small cell lung cancer (NSCLC) and liver metastases, in order to identify the optimal treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Bayesian network meta-analysis was performed using R software (version 4.2.3) and RevMan (version 5.4) to systematically compare the efficacy of various first-line treatment regimens, including chemotherapy, immunotherapy, and combination therapy, in patients with driver gene-negative NSCLC with liver metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 randomized controlled trials were included. Among patients with driver gene-negative NSCLC and liver metastases: (1) PD-1 inhibitor plus chemotherapy significantly improved progression-free survival (PFS) (HR\u00a0=\u00a00.572, 95% CI: 0.435\u20130.754) and overall survival (OS) (HR\u00a0=\u00a00.681, 95% CI: 0.559\u20130.830) compared with chemotherapy alone. (2) In the patients with non-squamous NSCLC, PD-1\/PD-L1 inhibitor plus chemotherapy resulted in a greater PFS benefit than chemotherapy alone. (3) A similar PFS advantage was observed in patients with squamous NSCLC receiving PD-1 inhibitor plus chemotherapy versus chemotherapy alone (HR\u00a0=\u00a00.583, 95% CI: 0.386\u20130.882). (4) Camrelizumab plus chemotherapy (CAM+CT) ranked highest in the network meta-analysis, with the top SUCRA values for both PFS (84.18%) and OS (96.38%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In treatment-naive driver gene-negative NSCLC with liver metastases: PD-1 inhibitor plus chemotherapy conferred more significant PFS and OS benefits than chemotherapy alone. CAM+CT appeared to rank favorably among the evaluated regimens, particularly in patients with squamous NSCLC and liver metastases, suggesting it may represent a candidate treatment strategy. However, given that these findings were derived from a network meta-analysis based on indirect comparisons, they should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42025632364<\/jats:ext-link>\n                      , identifier CRD42025632364.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1791664","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:44Z","timestamp":1784095904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of first-line treatment in driver gene-negative non-small cell lung cancer with liver metastases: a Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Weiqian","family":"Wu","sequence":"first","affiliation":[{"name":"Oncology Department, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Guo","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqi","family":"Dong","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyuan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shengjing Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2011.12.002","article-title":"Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer","volume":"13","author":"Gridelli","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.07.007","article-title":"Efficacy and safety of pemetrexed\/cisplatin versus gemcitabine\/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer","volume":"85","author":"Wu","year":"2014","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyd139","article-title":"Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis","volume":"30","author":"Maeda","year":"2000","journal-title":"Jpn J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","article-title":"Genomic variants associated with response to immune checkpoint inhibitors amongst asian patients with advanced NSCLC","volume-title":"Wclc","author":"Baramidze","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.06.020","article-title":"Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients","volume":"20","author":"Sridhar","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2022-111928","article-title":"Theory and practice of Bayesian and frequentist frameworks for network meta-analysis","volume":"28","author":"Sadeghirad","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","article-title":"A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102065","article-title":"Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial","volume":"8","author":"Borghaei","year":"2023","journal-title":"ESMO Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8502","article-title":"CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study","volume":"43","author":"Han","year":"2025","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","article-title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","volume":"19","author":"Yang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.3390\/cancers14174333","article-title":"The efficacy of PD-1\/PD-L1 inhibitors in patients with liver metastasis of non-small cell lung cancer: a real-world study","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30463","article-title":"Prognostic value of site-specific metastases in lung cancer: a population based study","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(96)00220-2","article-title":"Distribution of distant metastases from newly diagnosed non-small cell lung cancer","volume":"62","author":"Quint","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","article-title":"High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer","volume":"40","author":"Salcher","year":"2022","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130850","article-title":"Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC","volume":"4","author":"Kargl","year":"2019","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12935-024-03571-3","article-title":"Integration of the bulk transcriptome and single-cell transcriptome reveals efferocytosis features in lung adenocarcinoma prognosis and immunotherapy by combining deep learning","volume":"24","author":"Xie","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/jca.42531","article-title":"Identification of the key genes and characterizations of tumor immune microenvironment in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)","volume":"11","author":"Zhang","year":"2020","journal-title":"J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1296341","article-title":"PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment","volume":"14","author":"Parvez","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1039\/d3cp02795c","article-title":"Study on the allosteric activation mechanism of SHP2 via elastic network models and neural relational inference molecular dynamics simulation","volume":"25","author":"Liu","year":"2023","journal-title":"Phys Chem Chem Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-00550-y","article-title":"Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy","volume":"42","author":"Wang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"B44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.5246\/JCPS.2021.05.031","article-title":"Camrelizumab (SHR-1210), a humanized anti-PD-1 IgG4 mAb, exhibits superior anti-tumor activity and a favorable safety profile in preclinical studies","volume":"30","author":"Sun","year":"2021","journal-title":"J Chin Pharm Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2217\/imt-2021-0196","article-title":"Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8(+) T cells in lung cancer","volume":"14","author":"Liu","year":"2022","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:45Z","timestamp":1784095905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1791664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1791664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1791664"}}